Bone Therapeutics completes recruitment for spinal fusion study: 4 things to know

Biologics

Bone Therapeutics finished patient recruitment for its Phase IIA lumbar spinal fusion study.

Here are four things to know:

 

1. The study will test the ALLOB, the company's allogeneic bone-cell therapy product.

 

2. Bone Therapeutics anticipates having efficacy and safety data for the 32 patients by mid-2019.

 

3. The study will follow the patients for 12 months.

 

4. The interim results of the study revealed bone formation and pain improvement in patients with ALLOB.

 

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers